All In Biotech

Drug Trial Radar · NCT04958265

A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

A Phase III, Multicenter, Single-Arm Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Pediatric Patients With Atypical Hemolytic Uremic Syndrome (aHUS)

Last checked: Nov 20, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

41

Actual

Start

Nov 17, 2021

Primary completion

Jul 4, 2025

Study completion May 19, 2029

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
Collaborators
Chugai Pharmaceutical
First posted
Jul 12, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 28 days, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to evaluate the efficacy and safety of crovalimab in pediatric participants with aHUS.

Conditions

  • Atypical Hemolytic Uremic Syndrome

Interventions

  • CrovalimabDrug

    Crovalimab will be administered at a dose of 1000 mg intravenously (IV) (for participants weighing =\> 40 to \<100 kg) or 1500 mg IV (for participants weighing \>=100 kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, crovalimab will be administered at a dose of 340 mg subcutaneously (SC). On Week 5 and Q4W thereafter, it will be administered at a dose of 680 mg SC (for participants weighing =\> 40 to \<100 kg) or 1020 mg SC (for participants weighing \>=100 kg). Enrollment of participants weighing \<40 kg will be staggered using two weight-based dose confirmation groups (Group 1 participants weighing \>=20 kg to \<40 kg, followed by Group 2 participants weighing \>=5 kg to \<20 kg). All participants will receive an initial IV loading dose, which will be followed by SC dosing at either Q2W or Q4W intervals (depending on body weight), until study completion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Naïve Cohort: Percentage of Participants With Complete Thrombotic Microangiopathy Response (cTMAr) Anytime From Baseline to Week 25 (After 24 Weeks on Treatment)Time frame: From baseline up to Week 25

Locations

20 sites in 10 countries. Site status is shown where the registry gives one.

  • Children's Hospital Colorado

    Aurora, Colorado

  • University of Nebraska

    Omaha, Nebraska

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • UZ Gent

    Ghent, Belgium

  • UZ Leuven Gasthuisberg

    Leuven, Belgium

  • Inst. Da Criança- Faculdade de Medicina Usp

    São Paulo, São Paulo, Brazil

  • CHU Sainte-Justine

    Montreal, Quebec, Canada

  • Peking University First Hospital

    Beijing, China

  • Beijing Children's Hospital, Capital Medical University

    Beijing, China

  • The children's hospital , Zhejiang university school of medicine

    Hangzhou, China

  • Hôpital Arnaud de Villeneuve

    Montpellier, France

  • Gh Necker Enfants Malades

    Paris, France

  • Institute of Kidney Diseases and Research Centre

    Ahmedabad, Gujarat, India

  • Medanta-The Medicity

    Gurgaon, Haryana, India

  • All India Institute Of Medical Sciences (AIIMS)

    New Delhi, National Capital Territory of Delhi, India

  • Aichi Children?s Health and Medical Center

    Aichi, Japan

  • Chiba Children's Hospital

    Chibashi, Chibaken, Japan

  • Hospital de Especialidades Puerta de Hierro S.A de C.V.

    Zapopan, Mexico

  • Uniwersyteckie Centrum Kliniczne

    Gdansk, Poland

  • Instytut ?Centrum Zdrowia Matki Polki

    Lodz, Poland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.